Published online before print October 14, 2004, doi: 10.1161/01.ATV.0000147767.61336.de
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Thrombosis |
Increased Vascular Wall Thrombogenicity Combined With Reduced Blood Flow Promotes Occlusive Thrombus Formation in Rabbit Femoral Artery
From First Department of Pathology (A.Y., K.M., K.H., A.S., Y.A.) and the Department of Radiology (E.F., S.T.), Miyazaki Medical College, University of Miyazaki, Miyazaki; Pharmaceutical Research Laboratories (H.Y.), Ajinomoto Co, Inc, Kawasaki; and the Department of Medicine (Hematology) (Y.I.), Keio University School of Medicine, Tokyo, Japan.
Correspondence to Yujiro Asada MD, PhD, First Department of Pathology, Miyazaki Medical College, Miyazaki University, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. E-mail yasada{at}fc.miyazaki-u.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Objective— Plaque disruption does not always result in complete thrombotic occlusion. The mechanism of arterial thrombus propagation remains unclear.
Methods and Results— We studied how vascular wall thrombogenicity and blood flow reduction affect thrombus propagation using a rabbit model of single and repeated balloon injury. After balloon injury of the normal femoral artery, the blood flow was reduced to 50%, 25%, or 10% (n=5). Small mural thrombi composed of aggregated platelets were produced, but no occlusive thrombi developed in any flow reduction. Three weeks after the first balloon injury, neointima with tissue factor expression and increased procoagulant activity was developed. Balloon injury of the neointima with the same blood flow reduction (n=5) induced fibrin-rich thrombus formation. Additionally, injury with flow reduced to 25% and 10% promoted thrombus propagation resulting in vessel occlusion within 160±18 and 71±17 seconds, respectively. An injection of anti-von Willebrand factor (vWF) monoclonal antibody (AJW200; 1.0 mg/kg) prevented occlusive thrombus formation.
Conclusions— Increased vascular wall thrombogenicity together with a substantial blood flow reduction is crucial for occlusive thrombus formation, and vWF plays an important role in thrombus propagation. Reduced blood flow at plaque disruption sites might contribute to thrombus propagation leading to acute coronary syndromes.
We demonstrated in an animal model that increased vascular wall thrombogenicity combined with a blood flow reduction (>75%) promoted occlusive thrombus formation that was prevented by inhibiting plasma vWF. Reduced blood flow at plaque disruption sites might contribute to thrombus propagation and lead to acute coronary syndromes.
Key Words: thrombus propagation • blood flow • von Willebrand factor • tissue factor
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The rapid closure of coronary arteries caused by occlusive thrombi is the major cause of acute myocardial infarction. Disruption of coronary atherosclerotic plaques is recognized as one trigger of coronary thrombosis.1,2 However, this process does not always result in complete thrombotic occlusion with subsequent acute myocardial infarction. Because microscopic coronary thrombi are frequently detected during autopsies of noncardiac death,3,4 plaque disruption is considered a common complication and a high proportion of such events would be clinically silent.5 Therefore, whether thrombus on plaque disruption is occlusive or nonocclusive is critical to the onset of clinical events. Although the mechanisms of plaque rupture and thrombus formation in lesions have been intensively investigated, how arterial thrombi are propagated remains unclear.
See page 2207
The thrombotic response to plaque disruption is probably regulated by the thrombogenicity of exposed plaque constituents, local hemorheology, systemic thrombogenicity, and fibrinolytic activity.5 Many thrombotic factors are involved in acute thrombus formation. In particular, von Willebrand factor (vWF) binding to glycoprotein (platelet glycoprotein [GP]) Ib
and GP IIb-IIIa that plays an important role in platelet aggregation under conditions of rapid flow, might arise in atherosclerotic stenotic arteries.6–8 Tissue factor (TF) is a trigger of the extrinsic coagulation cascade. When simultaneously released from atheromatous plaques, TF potently activates the coagulation cascade leading to the formation of fibrin9 that contributes to the stabilization of initial and loosely packed platelet aggregates and to thrombus propagation during high blood flow. We demonstrated that thrombi on injured neointima are fibrin-rich in a model of repeated balloon injury even when blood flow is high.10 However, these thrombi remained exclusively mural and did not become occlusive.
Blood flow is a key modulator of thrombus propagation. After plaque disruption, coronary blood flow is frequently impaired, and microembolism together with microvascular constriction are considered to be contributing factors.11,12 Subsequent events would elevate distal vascular resistance, resulting in reduced blood flow at sites of plaque disruption. However, the effect of reduced blood flow on thrombus propagation in diseased arteries remains obscure.
We therefore examined whether reduced distal blood flow contributes to thrombus propagation and to subsequent occlusive thrombus formation in diseased arteries. We also examined the role of vWF in this process using a rabbit model of repeated balloon injury.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Rabbit Model of Single and Repeated Balloon Injury of Femoral Artery
We used 55 male Japanese white rabbits (Kyudo Corp, Kumamoto, Japan) weighing 2.5 to 3.0 kg in research protocols that were approved by the Animal Care Committee of Miyazaki Medical College (1998-025-6). All animals received humane care according to the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication 86-23, revised 1985). Aseptic surgery proceeded under general anesthesia induced by an intravenous injection of pentobarbital (25 mg/kg, body weight).
The rabbits were divided into single injury group (SI group) and repeated injury group (RI group). Blood flow rate (mL/min) in the femoral artery of each group was continuously measured by placing a Doppler flow probe over the femoral artery and with a transit time blood flowmeter (T106; Transonic Systems Inc). Data were analyzed using a digital recording system (PowerLab system; ADInstruments Pty Ltd). The sampling rate was 1000/sec. In SI group, a 2-French balloon catheter (Baxter Healthcare) was inserted via the anterior tibial arteries into the femoral artery and inflated at 1.4 atm, and then pulled down 2 times until 3 cm long. Immediately thereafter, the blood flow rate (mL/min) of the injured femoral artery was maintained or reduced to 50%, 25%, or 10% (n=5 each) by incomplete ligation of the distal femoral artery. The ligation was quantified by tightening a screw connected with the ligatures, and the blood flow was adjusted to each reduction level under continuous measurement (T106; Transonic Systems Inc). The RI group underwent repeated injury by inserting a 2.5-mm-diameter, 9-mm-long angioplasty balloon catheter (Boston Scientific Japan) via the carotid artery into the femoral artery. Briefly, the right common carotid artery was cannulated, and an angioplasty wire was fluoroscopically guided into the femoral artery. Thereafter, the angioplasty balloon was also fluoroscopically guided into the artery. The catheter was then inflated at 1.5 atm, and pulled back repeatedly 3 times until 5 cm. Three weeks after initial injury, the femoral arteries were imaged by angiography and the luminal diameter was measured. The arteries were subsequently injured in the same areas with a 2-French balloon catheter using the same procedure as used for the SI group.10 Immediately after the second injury, the blood flow rate of the injured artery was reduced to the same levels as those of the SI group (n=5 each). The role of vWF in arterial thrombus formation was evaluated by injecting an intravenous bolus of human anti-vWF monoclonal antibody (AJW200; at doses of 1.0 mg/kg) or saline (as control) via the ear vein 30 minutes before the second balloon injury. This antibody reacts with the A1 domain of vWF in some species, including humans and rabbits.13,14 The antibody dosage used in this study significantly inhibited botrocetin-induced platelet aggregation over the next 24 hours, and did not affect collagen-induced platelet aggregation and systemic coagulation as described.10 Thirty minutes after the single or second injury, the rabbits were injected intravenously with heparin (500 U/kg) and euthanized 5 minutes later with an overdose of pentobarbital (60 mg/kg, intravenous) to evaluate thrombus formation. The animals were perfused with 50 mL of 0.01 mol/L phosphate-buffered saline, followed by perfusion fixation with 100 mL of 4% paraformaldehyde for immunohistochemical evaluation or with 4% neutralized formaldehyde and 1% glutaraldehyde in 0.1 mol/L phosphate buffer for electron microscopy. The femoral arteries were dissected out for subsequent studies.
Light Microscopy and Immunohistochemistry
The femoral arteries were fixed in 4% paraformaldehyde for 24 hours at 4°C and embedded in paraffin. Sections (3-µm-thick) were stained with hematoxylin and eosin/Victoria blue dye and immunohistochemically examined using antibodies against -smooth muscle actin (HHF35; DAKO Japan), rabbit macrophages (RAM11; DAKO Japan), GP IIb-IIIa (Affinity Biologicals Inc), rabbit fibrin (a gift from Dr T. Kurokawa, Takeda Chemical Industries, Ltd),15 vWF (The Binding Site), and tissue factor (The Chemo-Sero-Therapeutic Research Institute).10,16
Transmission Electron Microscopy
Small pieces of injured arteries were immersion-fixed with the same fixative for 12 hours at 4°C, post-fixed with 2% OsO4 in phosphate buffer for 90 minutes at room temperature, and embedded in Epon 812. Ultrathin sections were stained with uranyl acetate and lead citrate and examined using a JEOL 1200EX (Nihon Denshi, Japan).
Tissue Factor Activity of Femoral Artery
The intima and media of the femoral arteries without perfusion fixation were carefully separated from the adventitia. The activity of TF was measured and expressed in arbitrary units (AU) as described.17 The protein concentration was determined using the Bradford reagent (Bio-Rad Laboratories).
Statistical Analysis
Data are expressed as means±standard error. The unpaired Student t test or Fisher exact test evaluated differences between individual groups. P<0.05 was considered significant (n indicates the number of animals studied).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Luminal Stenosis and Neointimal Formation in Femoral Arteries After Initial Injury of RI
Angiographs and microphotographs of rabbit femoral arteries obtained 3 weeks after the initial balloon injury revealed luminal stenosis and neointimal formation at injured (Figure IA and IC, available online at http://atvb.ahajournals.org), but not at uninjured (Figure IA and IB) sites. The luminal diameters in the injured and uninjured arteries were 0.98±0.06 mm and 1.62±0.07 mm (n=5, P<0.01). Immunohistochemistry demonstrated that the neointima was composed exclusively of smooth muscle cells and extracellular matrix (data not shown).
Localization and Activity of Tissue Factor in Femoral Arteries
Tissue factor immunoreactivity in the neointima and adventitia was diffuse and intense (Figure 1). The activity of TF was significantly increased in the injured neointima (1496±180 AU/mg protein) and media than in normal intima and media (694±164 AU/mg protein, n=4 each, P<0.05).
|
Blood Flow Reduction and Thrombus Formation on Injured Femoral Arteries
We continuously monitored blood flow (mL/min) through the injured femoral artery. Blood flow in the SI group was preserved for at least 30 minutes after injury, even when reduced to 50%, 25%, and 10% (Figure 2A through 2D; Table). Blood flow was also preserved without or with 50% reduction in the RI group, but the flow deteriorated after reduction to 25% and 10% and disappeared within 160±18 and 71±17 seconds, respectively (Figure 2E through 2G; Table). A bolus injection of AJW200 (1.0 mg/kg) significantly inhibited blood flow deterioration after a flow reduction in the arteries with RI (Figure 2H; Table).
|
|
The first balloon injury induced the formation of small mural thrombi that were mainly composed of aggregated platelets, regardless of different blood flow reduction in the all animals (n=5 each) (Figure 3A through 3D). In contrast, RI of the neointima induced mural thrombi composed of fibrin and aggregated platelets with or without blood flow reduction (Figure 3E through 3H). RI without or with 50% blood flow reduction did not generate occlusive thrombi (n=5 each) (Figure 3E and 3F), but 4 of 5 animals of the RI group with 75% flow reduction and all 5 animals of the RI group with 90% flow reduction had occlusive thrombi (Figure 3G; Table). All occlusive thrombi were positive for GP IIb-IIIa, fibrin, vWF, and TF (Figure 4).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The main findings of this study were that a combination of increased vascular thrombogenicity and a reduction in blood flow of >75% promoted occlusive thrombus formation in rabbit femoral arteries. Either condition alone induced mural, but not occlusive, thrombi. In addition, anti-vWF monoclonal antibody prevented the formation of occlusive thrombi.
Atherosclerotic plaque disruption is a key event in the pathogenesis of acute coronary syndromes1,2 that does not always result in complete thrombotic occlusion of coronary arteries. Although the prevalence of silent plaque disruption in the clinical population is unknown, studies of autopsies have detected coronary thrombosis in up to 8% of individuals with coronary atheroma who died of noncardiac causes.3,4 Therefore, whether thrombi remain mural or become occlusive is crucial to the onset of cardiovascular events. Groves et al18 reported that mural thrombi produced by repeated balloon injury of the rabbit aorta rapidly became nonreactive to further thrombus propagation and disappeared from the surface within a few days after injury. Our previous studies also demonstrated that the repeated balloon injuries of rabbit aortas and femoral arteries induce fibrin-rich mural thrombi, but do not become occlusive.10,17 These results suggest that not only increased vascular thrombogenicity but also other factors are required to propagate arterial occlusive thrombi.
Blood flow is one of the most important modulators of thrombus formation and propagation. Plaque disruption initiates thrombus formation at the disrupted site and frequently causes a reduction in coronary blood flow. This mechanism is considered to be largely responsible for the rapid elevation of distal vascular resistance because of microvascular embolism and vasoconstriction.5,11,12 Autopsy studies have identified microemboli in 54% to 79% of patients who died of ischemic heart disease.19–21 In addition to aggregated platelets and fibrin, several potent vasoactive substances are released from disrupted atheromatous plaques that can cause microvascular embolism and constriction.5,11,12 Such events would subsequently reduce coronary blood flow at disrupted sites. Some animal studies have revealed that the rupture of atherosclerotic lesions induces rapid and obvious increases in distal vascular resistance caused by severe microvascular constriction,22 and that coronary microembolism induces a transient decrease of coronary blood flow.23 Bonderman et al24 have emphasized the importance of circulating TF released from disrupted plaques in this process. A clinical study has found 
80% reduction in coronary blood flow during ischemia in patients with unstable angina.25 Many clinical reports have indicated that in spontaneous plaque rupture and ulceration and also during coronary intervention, induced microembolization leads to a reduction in coronary flow reserve.26 Therefore, our animal model partly simulates the onset of cardiovascular events after plaque disruption.
The coagulation system contributes to the pathogenesis of acute coronary syndromes.5,27 This system is readily activated when blood flow is reduced.28 We therefore assumed that thrombi produced by a single balloon injury with blood flow reduction would be fibrin-rich. However, we found that the thrombi on normal vessels consisted exclusively of aggregated platelets, suggesting that increased thrombogenicity of the vascular wall is more crucial for fibrin-rich thrombus formation than blood flow reduction.
Recent studies have discovered that vWF plays a crucial role in platelet aggregation under rapid flow conditions.6,7,8 We and others have also demonstrated the contribution of vWF to the interaction between platelets and fibrin29,30 and also fibrin-rich thrombus formation.10 The occlusive thrombi in this study were composed of a large amount of fibrin and platelets and were rich in vWF. The presence of vWF in the occlusive thrombi suggests that vWF plays an important role in this process. A bolus injection of a monoclonal antibody against vWF (AJW200) obviously inhibited occlusive thrombus formation. Although the result seems to be unusual because crucial roles of vWF have been demonstrated under high shear stress, recent studies suggest that vWF plays a significant role under low-shear or disturbed flow conditions.31,32 The present results also indicate that vWF plays a considerable role in fibrin-rich thrombus propagation, even when blood flow is reduced or disturbed.
Occlusive thrombi were rich in TF. Himber et al33 have revealed that active TF is localized in human thrombi, where it was associated with platelets, fibrin, monocytes, and polymorphonuclear leukocytes. Our results support this observation. Whether intravascular TF originate from leukocytes, platelets, or other cells remains controversial. Rauch et al34 reported the transfer of TF from monocytes and polymorphonuclear leukocytes to platelets. Conversely, more recent studies have indicated that active TF are located in circulating microvesicles and in activated platelets.35,36 Although our results do not address this issue, the increased concentration and activity of plasma TF induced by blood flow alteration seems to accelerate thrombus propagation.
In conclusion, our results suggest that a combination of increased vascular wall thrombogenicity and blood flow reduction is crucial for occlusive thrombus formation in arteries, and that vWF plays an important role in this process. Considerable reduction of coronary blood flow at plaque disruption sites may contribute to thrombus propagation and lead to acute coronary events.
|
Acknowledgments |
|---|
This study was supported in part by grants-in-aid from Scientific Research (c) (No.14570153) and from 21st COE Research (Life Science) from the Ministry of Education, Science, Sports, and Culture, Japan.
Received August 2, 2004; accepted September 20, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992; 326: 242–250.[Medline] [Order article via Infotrieve]
2. Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999; 41: 323–333.
3. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984; 310: 1137–1140.[Abstract]
4. Arbustini E, Grasso M, Diegoli M, Morbini P, Aguzzi A, Fasani R, Specchia G. Coronary thrombosis in non-cardiac death. Coron Artery Dis. 1993; 4: 751–759.[Medline] [Order article via Infotrieve]
5. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. Circulation. 1996; 94: 2013–2020.
6. Ruggeri ZM. Perspective series: Cell adhesion in vascular biology. von Willebrand factor. J Clin Invest. 1997; 99: 559–564.[Medline] [Order article via Infotrieve]
7. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest. 1998; 101: 479–486.[Medline] [Order article via Infotrieve]
8. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest. 2000; 105: 783–791.[Medline] [Order article via Infotrieve]
9. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 1999; 99: 1780–1787.
10. Yamashita A, Asada Y, Sugimura H, Yamamoto H, Marutsuka K, Hatakeyama K, Tamura S, Ikeda Y, Sumiyoshi A. Contribution of von Willebrand Factor in thrombus formation on neointima of rabbit stenotic iliac artery under high blood flow velocity. Arterioscler Thromb Vasc Biol. 2003; 23: 1105–1110.
11. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000; 101: 570–580.
12. Skyschally A, Erbel R, Heusch G. Coronary microembolization. Circ J. 2003; 67: 279–286.[CrossRef][Medline] [Order article via Infotrieve]
13. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997; 122: 165–171.[CrossRef][Medline] [Order article via Infotrieve]
14. Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, Ikeda Y, Yoshimoto R. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol. 2002; 22: 187–192.
15. Kurokawa T, Iwasa S, Kakinuma A, Stassen JM, Lijnen HR, Collen D. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Thromb Haemost. 1991; 66: 684–693.[Medline] [Order article via Infotrieve]
16. Asada Y, Hara S, Tsuneyoshi A, Hatakeyama K, Kisanuki A, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Fibrin-rich and platelet rich thrombus formation on neointima: Recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost. 1998; 80: 506–511.[Medline] [Order article via Infotrieve]
17. Atsuchi N, Nishida T, Marutsuka K, Asada Y, Kamikubo Y, Takeshita A, Ueno H. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-Injured rabbit carotid arteries. Circulation. 2001; 103: 570–575.
18. Groves HM, Kinlough-Rathbone RL, Richardson M, Jorgensen L, Moore S, Musterd JF. Thrombin generation and fibrin formation following injury to rabbit neointima. Studies of vessel wall reactivity and platelet survival. Lab Invest. 1982; 46: 605–612.[Medline] [Order article via Infotrieve]
19. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985; 71: 699–708.
20. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation. 1986; 73: 418–427.
21. Frink RJ, Rooney PA, Trowbridge JO, Rose JP. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial Infarction. Br Heart J. 1988; 59: 196–200.
22. Taylor AJ, Bobik A, Berndt MC, Ramsay D, Jennings G. Experimental rupture of atherosclerotic lesions increases distal vascular resistance. A limiting factor to the success of infarct angioplasty. Arterioscler Thromb Vasc Biol. 2002; 22: 153–160.
23. West JW, Kobayashi T, Anderson FS. Effects of selective coronary embolization on coronary blood flow and coronary sinus venous blood oxygen saturation in dogs. Circ Res. 1962; 10: 722–738.
24. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyosi M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood. 2002; 99: 2794–2800.
25. Marzilli M, Sambuceti G, Fedele S, L’Abbate A. Coronary microcirculatory vasoconstriction during ischemia in patients with unstable angina. J Am Coll Cardiol. 2000; 35: 327–334.
26. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol. 2000; 36: 22–24.
27. Rentrop KP. Thrombi in acute coronary syndromes. Revisited and revised. Circulation. 2000; 101: 1619–1626.
28. Gemmell CH, Turitto VT, Nemerson Y. Flow as a regulator of the activation of factor X by tissue factor. Blood. 1988; 72: 1404–1406.
29. Loscalzo J, Inbal A, Handin RI. von Willebrand protein facilitates platelet incorporation in polymerizing fibrin. J Clin Invest. 1986; 78: 1112–1119.
30. Endenburg SC, Hantgan RR, Lindeboom-Blokzijl L, Lankhof H, Jerome WG, Lewis JC, Sixma JJ, de Groot PG. On the role of von Willebrand factor in promoting platelet adhesion to fibrin in flowing blood. Blood. 1995; 86: 4158–4165.
31. Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000; 96: 3322–3328.
32. Methia N, Andre P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood. 2001; 98: 1424–1428.
33. Himber J, Kling D, Fallon JT, Nemerson Y, Riederer MA. In situ localization of tissue factor in human thrombi. Blood. 2002; 99: 4249–4250.
34. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000; 96: 170–175.
35. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003; 17: 476–478.
36. Camera M, Frigerio M, Toschi V, Brambilla M, Rossi F, Cottell DC, Maderna P, Parolari A, Bonzi R, De Vincenti O, Tremoli E. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol. 2003; 23: 1690–1696.
Related Article:
Arterioscler Thromb Vasc Biol 2004 24: 2207-2208.
This article has been cited by other articles:
 |
|
 |
|
  Y. Takemoto, H. Kawata, T. Soeda, K. Imagawa, S. Somekawa, Y. Takeda, S. Uemura, M. Matsumoto, Y. Fujimura, J.-i. Jo, et al. Human Placental Ectonucleoside Triphosphate Diphosphohydrolase Gene Transfer via Gelatin-Coated Stents Prevents In-Stent Thrombosis Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 857 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ishii, F. Vinuela, Y. Murayama, I. Yuki, Y.L. Nien, D.T. Yeh, and H.V. Vinters Swine model of carotid artery atherosclerosis: experimental induction by surgical partial ligation and dietary hypercholesterolemia. AJNR Am. J. Neuroradiol., October 1, 2006; 27(9): 1893 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goto Propagation of Arterial Thrombi: Local and Remote Contributory Factors Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2207 - 2208. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||